PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring the importance and urgency of addressing optic neuritis, a serious condition that can have negative ...
The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve ...